Skip to content
Parakho

Fermenta Biotech Ltd

NSE FERMENTABSE 506414fermentabiotech.com

Q1 FY27, unaudited

Revenue
₹121.82 Cr
Profit after tax
₹9.53 Cr

As filed with the exchange, consolidated basis.

Statement of profit and loss

Figures in ₹ crore, reproduced from the results data files the company filed with BSE and NSE under Regulation 33 of the SEBI (LODR) Regulations. Nothing is restated, adjusted or estimated.

Statement of profit and loss, consolidated basis
₹ croreQ1 FY27vs a year agoFY26
Revenue from operations121.82−10.60%525.43
Other income4.37−50.14%22.39
Total income126.20−12.99%547.81
Employee benefit expense23.01+13.05%82.59
Finance costs2.54−18.23%11.54
Depreciation & amortisation5.20−10.61%21.70
Total expenses111.50−4.65%458.83
Profit before tax14.69−47.69%95.86
Tax expense5.16−20.44%25.61
Profit after tax9.53−55.88%70.25
Total comprehensive income9.83−48.10%63.65
Earnings per share
Earnings per share, basic₹3.40₹24.70
Earnings per share, diluted₹3.34₹24.51

Q1 FY27 — unaudited, from the company’s filing with NSE. Source

Q1 FY26, the year-ago base — unaudited, from the company’s filing with BSE. Source

FY26 — from the company’s filing with BSE. Source

Q1 FY27 results for every company Parakho holds

Earnings call

Fermenta Biotech Ltd has not filed a concall transcript in the last 4 quarters.

Filings

12 shown · 67 published by the exchange

BSE corporate announcements, classified by Parakho. The exchange’s own category is kept alongside our classification so a reclassification never rewrites history.

Industry

Healthcare › Pharmaceuticals

Classification as published by BSE.

Companies also in Pharmaceuticals, in alphabetical order

All 196 companies in Pharmaceuticals

Page generated from filings held to 09 Oct 2026.